Full interview: Xphyto Therapeutics acquires Vektor Pharma as company looks for rapid growth
Xphyto Therapeutics (CSE: XPHY) CEO Hugh Rogers sat down with Steve Darling from Proactive Vancouver with details about a key acquisition the company has made buying Vektor Pharma. They are a small German narcotics company.
Rogers telling Proactive why this deal will accelerate the company’s plans for medical cannabis in Germany. Rogers also shared details about the thin film delivery system they have also acquired.
Quick facts: Xphyto Therapeutics Corp.
Market Cap: $60.77 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Xphyto Therapeutics Corp. named herein, including the promotion by the Company of Xphyto Therapeutics Corp. in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE